The active compound in the best-selling drug Ozempic markedly lowers the risk of complications from chronic kidney disease, according to a multiyear study published Friday — a finding that could ...

Ozempic is already approved to treat T2D, for cardiovascular risk reduction ... worsening kidney disease and cardiovascular death in people with T2D and CKD. …as Rybelsus cuts MACE in type ...

A new study suggests that semaglutide, the active ingredient in Ozempic, may help decrease liver fat, inflammation, and ...

The announcement follows new research that suggested drugs like Wegovy, Mounjaro and Ozempic slashed the risk of contracting the disease. Scientists from Israel said the drugs, also known as GLP ...

The cutting-edge weight-loss drug Ozempic/Wegovy can stop and even reverse fatty liver disease, a new clinical trial has found. Nearly twice as many people taking semaglutide stopped their fatty ...